bpc-157 neuroprotective properties as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers BPC-157 & The Gut-Brain Axis:

There's no need for the NCAA to prove it's a performance-enhancer (though they believe it is)

Is my consultation really free?+ Yes

Environment is stabilized first

The "rapid reversal" group (approximately 10-15% of users) experiences concerning quick benefit loss within weeks of discontinuation, typically involving users who applied very high concentrations creating dependency-like patterns, possessed severe underlying skin conditions requiring ongoing treatment, experienced significant lifestyle or environmental stressors overwhelming skin resilience, discontinued abruptly without tapering from high-dose protocols, or had unrealistic perception inflation during treatment leading to exaggerated reversal perception

Human data are limited and mixed: Clinical studies have largely assessed safety and metabolism, while weight-related outcomes were modest and inconsistent